Welcome to LookChem.com Sign In|Join Free
  • or
L-Aspartic acid, N-[(phenylMethoxy)carbonyl]-L-alanyl-, 24-(1,1-dimethylethyl) ester (9CI) is a complex organic compound with the chemical formula C21H27N2O6. It is a derivative of L-aspartic acid, an amino acid that plays a crucial role in various metabolic processes in the body. This specific compound features a phenylmethoxycarbonyl group attached to the L-alanyl residue, which is further esterified with a 1,1-dimethylethyl group. The compound is characterized by its molecular structure, which includes a peptide bond between the aspartic acid and alanine residues, and an ester linkage with the 1,1-dimethylethyl group. L-Aspartic acid, N-[(phenylMethoxy)carbonyl]-L-alanyl-, 24-(1,1-diMethylethyl) ester (9CI) is of interest in the field of organic chemistry and may have potential applications in pharmaceuticals or as a research tool in studying peptide chemistry.

3408-50-2

Post Buying Request

3408-50-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3408-50-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3408-50-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,0 and 8 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 3408-50:
(6*3)+(5*4)+(4*0)+(3*8)+(2*5)+(1*0)=72
72 % 10 = 2
So 3408-50-2 is a valid CAS Registry Number.

3408-50-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name [(N-benzyloxycarbonyl)-L-alaninyl]-L-aspartic acid [beta]-tert-butyl ester

1.2 Other means of identification

Product number -
Other names L-Aspartic acid, N-[(phenylmethoxy)carbonyl]-L-alanyl-, 24-(1,1-dimethylethyl) ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3408-50-2 SDS

3408-50-2Relevant academic research and scientific papers

METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE

-

Paragraph 00158, (2017/07/14)

Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

-

Paragraph 0159, (2016/08/17)

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

First-in-class pan caspase inhibitor developed for the treatment of liver disease

Linton, Steven D.,Aja, Teresa,Armstrong, Robert A.,Bai, Xu,Chen, Long-Shiuh,Chen, Ning,Ching, Brett,Contreras, Patricia,Diaz, Jose-Luis,Fisher, Craig D.,Fritz, Lawrence C.,Gladstone, Patricia,Groessl, Todd,Gu, Xin,Herrmann, Julia,Hirakawa, Brad P.,Hoglen, Niel C.,Jahangiri, Kathy G.,Kalish, Vincent J.,Karanewsky, Donald S.,Kodandapani, Lalitha,Krebs, Joseph,McQuiston, Jeff,Meduna, Steven P.,Nalley, Kip,Robinson, Edward D.,Sayers, Robert O.,Sebring, Kristen,Spada, Alfred P.,Ternansky, Robert J.,Tomaselli, Kevin J.,Ullman, Brett R.,Valentino, Karen L.,Weeks, Suzanne,Winn, David,Wu, Joe C.,Yeo, Pauline,Zhang, Cheng-Zhi

, p. 6779 - 6782 (2007/10/03)

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3408-50-2